The results in these patients with relapsed/refractory B-ALL suggest that direct bispecific CD19/CD22 CAR T cells may be necessary to preempt antigen escape without exacerbating toxicity. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.